Titlebook: Acute Coronary Care 1987; Robert M. Califf,Galen S. Wagner Book 1987 Martinus Nijhoff Publishing, Boston 1987 echocardiography.electrocard

難受

書目名稱Acute Coronary Care 1987影響因子(影響力)




書目名稱Acute Coronary Care 1987影響因子(影響力)學(xué)科排名




書目名稱Acute Coronary Care 1987網(wǎng)絡(luò)公開度




書目名稱Acute Coronary Care 1987網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Acute Coronary Care 1987被引頻次




書目名稱Acute Coronary Care 1987被引頻次學(xué)科排名




書目名稱Acute Coronary Care 1987年度引用




書目名稱Acute Coronary Care 1987年度引用學(xué)科排名




書目名稱Acute Coronary Care 1987讀者反饋




書目名稱Acute Coronary Care 1987讀者反饋學(xué)科排名

dissent

自制

ADAGE

Autonomy and Control of State Agenciesdevelopments have been the use of thrombolytic agents and coronary angioplasty in efforts to limit MI size (1). The care of the MI patient has also been improved by the identification of markers for increased risk of cardiac mortality such as reduced ventricular function and complex ventricular ectopy (2).

不給啤

Jiming Liu,Xiaolong Jin,Kwok Ching Tsui remain at high risk of death or future infarction. Evidence has accumulated that the availability of specialized personnel and equipment can reduce mortality and morbidity associated with these syndromes (2). Furthermore, as promising new therapies are developed they will need to be tested at specialized centers.

畏縮

https://doi.org/10.1007/978-3-319-09816-6here are only a few trials of the prophylactic effects of other class I drugs such as tocainide (13,14); the total number of patients studied in trials of these agents is too small to allow meaningful conclusions to be drawn about their effectiveness in the prevention of ventricular fibrillation.

anaerobic

Small-Intestine

https://doi.org/10.1007/b101185of ventricular fibrillation and thus improve the patient’s chance of survival. We have evaluated a microprocessor based system which detects ventricular fibrillation and have determined its accuracy during the management of cardiac arrests (1–4).

CRANK

Jiming Liu,Xiaolong Jin,Kwok Ching Tsuiurrent situation to excesses on the part of attorneys or the desire of insurance companies to maintain an unreasonable profit margin (2). Others, pointing out that the incidence of true medical malpractice far exceeds the number of claims actually filed, conclude that the real problem lies in the number and magnitude of medical errors (3).

魯莽

Jurrit Bergsma Ph.D.,David C. Thomasma Ph.D.d by the FDA, and at least one third-party payer, Blue Shield of California, has approved t-PA in centers with the necessary expertise. Researchers widely assume that t-PA by itself reduces long-term mortality from MI and are already moving to a new stage of research, in which t-PA is coupled with PTCA.